Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer

Drugs of Today

Volumn 49, Issue 11, 2013, Pages 701-715

  Haddley, K ^a  

^a NONE

Author keywords

Antibody drug conjugates; Breast cancer therapy; Cytochrome P450 3a4 inhibitors; Trastuzumab emtansine; Trastuzumab DM1

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; PICTILISIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TREBANANIB;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BOLUS INJECTION; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CELLULITIS; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IC 50; IMMEDIATE EARLY GENE; LEUKOPENIA; LIMB PAIN; LOSS OF FUNCTION MUTATION; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA; NEUTROCYTOPENIA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR BIOPSY; TUMOR VOLUME; VOMITING;

EID: 84890403198     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.11.2020937     Document Type: Article

References (65)

1. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer: Lyon, France 2010. http://globocan.iarc.fr. Accessed October 22, 2013.
2. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49(6): 1374-403.
3. Swaminathan, R., Lucas, E., Sankaranarayanan, R. Cancer survival in Africa, Asia, the Caribbean and Central America: database and attributes. IARC Sci Publ 2011, (162): 23-31.
4. American Cancer Society. Cancer Facts & Figures 2013. American Cancer Society: Atlanta 2013.
5. Owens, M.A., Horten, B.C., Da Silva, M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5(1): 63-9.
6. Klapper, L. N. Glathe, S., Vaisman, N., Hynes, N.E., Andrews, G.C., Sela, M., Yarden, Y. The ErbB2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999, 96(9): 4995-5000.
7. Sliwkowski, M.X., Schaefer, G., Akita, R.W. et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994, 269(20): 14661-5.
8. Yarden, Y., Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2): 127-37.
9. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785): 177-82.
10. Chazin, V.R., Kaleko, M., Miller, A.D., Slamon, D.J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992, 7(9): 1859-66.
11. Mezzelani, A., Alasio, L., Bartoli, C., Bonora, M.G., Pierotti, M.A., Rilke, F., Pilotti, S. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999, 80(3-4): 519-25.
12. Graus-Porta, D., Beerli, R.R., Hynes, N.E. Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995, 15(3): 1182-91.
13. Beerli, R.R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., Hynes, N.E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 1995, 15(12): 6496-505.
14. Fazioli, F., Kim, U-H., Rhee, S., Molloy, C.J., Segatto, O., Di Fiore, P.P. The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-g and CTP-ase activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol 1991, 11(4): 2040-8.
15. Magnifico, A., Albano, L., Campaner, S., Campiglio, M., Pilotti, S., Ménard, S., Tagliabue, E. Protein kinase C alpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res 2007, 67(11): 5308-17
16. Garcia, R., Yu, C.L., Hudnall, A. et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997, 8(12): 1267-76.
17. Slamon, D.J, Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11): 783-92.
18. Buzdar, A.U., Ibrahim, N.K, Francis, D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23(16): 3676-85.
19. Nielsen, D.L., Andersson, M., Kamby, C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35(2): 121-36.
20. Yin, W., Jiang, Y., Shen, Z., Shao, Z., Lu, J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One 2011, 6(6): e21030.
21. Robert, N., Leyland-Jones, B., Asmar, L. et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006, 24(18): 2786-92.
22. Burstein, H.J., Keshaviah, A., Baron, A.D. et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007, 110(5): 965-72.
23. Bengala, C., Zamagni, C., Pedrazzoli, P. et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006, 94(7): 1016-20.
24. Kelly, H., Kimmick, G., Dees, E.C. et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006, 7(3): 237-43.
25. Perez, E.A., Suman, V.J., Davidson, N.E. et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26(8): 1231-8.
26. Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6(4): 443-6
27. Junttila, T.T., Li, G., Parsons, K., Phillips, G.L., Sliwkowski, M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011, 128(2): 347-56.
28. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., Jain, R.K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416(6878): 279-80.
29. th Annu Meet Am Assoc Cancer Res (AACR) (April 6-10, Washington, D.C.) 2013, Abst 537.
30. Bedard, P.L., de Azambuja, E., Cardoso, F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 2009, 9(2): 148-62.
31. Coughlin, C.M., Johnston, D.S., Strahs, A. et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat 2010, 124(1): 1-11.
32. Scaltriti, M., Eichhorn, P.J., Cortes, J. et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011, 108(9): 3761-6.
33. Khoury, T., Mojica, W., Hicks, D., Starostik, P., Ademuyiwa, F., Janarthanan, B., Cheney, R.T. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Mod Pathol 2011, 24(8): 1055-9.
34. Sperinde, J., Jin, X., Banerjee, J. et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010, 16(16): 4226-35.
35. Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009, 69(24): 9330-6.
36. Lewis Phillips, G.D., Li, G., Dugger, D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68(22): 9280-90.
37. Erickson, H.K., Lewis Phillips, G.D., Leipold, D.D. et al. The effect of different linkers on target cell catabolism and pharmacokinetics/ pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012, 11(5): 1133-42.
38. Krop, I.E., Beeram, M., Modi, S. et al. Phase I study of trastuzumab-DM1 on HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28(16): 2698-704.
39. Lewis Phillips, G.D., Fields, C.T., Crocker, L. et al. Potent anti-tumor activity of trastuzumab-DM1 antibody-drug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 2133.
40. Fields, C., Crocker, L.M., Sliwkowski, M.X., Lewis Phillips, G.D. Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab. Proc Am Assoc Cancer Res (AACR) 2010, 51: Abst 5607.
41. Fields, C., Li, G., Prior, W.W., Parsons, K., Sampath, D., Lewis Phillips, G.D. Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 3239.
42. Parsons, K., Fields, C., Gunter, B. et al. Potent anti-tumor activity of T-DM1 antibody-drug conjugate in combination with chemotherapeutic agents in breast tumor cells. Eur J Cancer Suppl [22nd EORTC-NCI-AACR Symp Mol Targets Cancer Ther (November 16-19, Berlin) 2010] 2010, 8(7): Abst 86.
43. Shen, B., Bumbaca, D., Saad, O. et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): An emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012, 13(7): 901-10.
44. Krop, I.E., Beeram, M., Modi, S. et al. Phase I study of trastuzumab-DM1,an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28(16): 2698-704.
45. Beeram, M., Krop, I.E., Burris, H.A. et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012, 118(23): 5733-40.
46. Hurvitz, S.A., Dirix, L., Kocsis, J. et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013, 31(9): 1157-63.
47. Burris, H.A. 3rd., Rugo H.S., Vukelja, S.J. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29(4): 398-405.
48. Krop, I.E., Lorusso, P., Miller, K.D. et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012, 30(26): 3234-41.
49. A phase II, open-label study to evaluate corrected QT interval effects of trastuzumab-MCC-DM1 (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and tolerability of combined T-DM1 and pertuzumab in patients with early disease progression while receiving T-DM1 alone (NCT00943670). ClinicalTrials.gov Web site. Accessed October 23, 2013.
50. nd Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-5, Dallas) 2011] 2011, 89(Suppl. 1): Abst P11-64.
51. A phase Ib/II, open-label study of the safety, tolerability and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancer who have previously received trastuzumab (NCT00875979). ClinicalTrials.gov Web site. Accessed October 24, 2013.
52. Verma, S., Miles, D., Gianni, L. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367(19): 1783-91.
53. Welslau, M., Dieras, V., Sohn, J.-H. et al. Patient-reported outcomes (Pros) from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs. capecitabine and lapatinib (XL) in HER2-positive locally advanced or MBC. Eur Soc Med Oncol (ESMO) Sci Edu Conf (September 28-October 2, Vienna) 2012, Abst 329P.
54. Perez, E.A., Hurvitz, S., Amler, L.C. et al. Exploratory analysis of the relationship between HER2 expression (by qRT-PCR) and efficacy with first-line trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (HT) in a randomized phase 2 study of patients (pts) with HER2-positive MBC. Eur Soc Med Oncol (ESMO) Sci Edu Conf (September 28-October 2, Vienna) 2012, Abst 226P.
55. th Annu Meet Am Assoc Cancer Res (AACR) (April 6-10, Washington, D.C.) 2013, Abst LB-63.
56. Olson, E.M., Lin, N.U., Dipiro, P.J., Najita, J.S., Krop, I.E., Winer, E.P., Burnstein, H.J. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol 2012, 23(1): 93-7.
57. th Annu San Antonio Breast Cancer Symp (December 4-8, San Antonio) 2012, Abst P5-18-06.
58. Burris, H.A. 3rd. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011, 11(6): 807-19.
59. Thon, J.N., Devine, M.T., Jurak Begonja, A., Tibbitts, J., Italiano, J.E. Jr. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012, 120(10): 1975-84.
60. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010, Abst 1012.
61. th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012, Abst 532.
62. Barok, M., Tanner, M., Koeninki, K., Isola, J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011, 306(2): 171-9.
63. th Annu Meet Soc Gynecol Invest (March 20-23, Orlando) 2013, Abst S-237.
64. th Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 12-17, National Harbor) 2012] 2012, 91(Suppl. 1): Abst P11-40.
65. th Annu San Antonio Breast Cancer Symp (December 4-8, San Antonio) 2012, Abst P5-18-16.